

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/811,508
Filing Date	March 26, 2004
First Named Inventor	Xing Cheng
Group Art Unit	4659-1648
Examiner Name	Unassigned Chen, Stacy
Attorney Docket Number	26-003820US
Date Submitted	December 9, 2004

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
SK	1	6,225,091		Klein et al	05-01-2001	
SK	2	6,713,066		Collins et al	03-30-2004	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
SK	3	WO	2002/44334		Aviron et al	06-06-2002		
SK	4	WO	2004/028478		MedImmune Vaccines, Inc. et al.	04/08/2004		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
SK	5	Bermingham and Collins (1999) "The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription" <u>Proc. Natl. Acad. Sci. USA</u> 96:11259-11264.	
↓	6	Cheng et al. (2001) "Chimeric subgroup A respiratory syncytial virus with the glycoproteins substituted by those of subgroup B and RSV without the M2-2 gene are attenuated in African green monkeys" <u>Virology</u> 283:59-68.	
↓	7	Collins et al. (1995) "Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development" <u>Proc. Natl. Acad. Sci.</u> 92:11563-11567	

Examiner Signature	Stacy B Chen	Date Considered	1/3/06
-----------------------	--------------	--------------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)	Substitute for form 1449A-B/PTO		Complete if Known	
			Application Number	10/811,508
			Filing Date	March 26, 2004
			First Named Inventor	Xing Cheng
			Group Art Unit	1653-1648
			Examiner Name	Unassigned chen, Stacy
			Attorney Docket Number	26-003820US
		Date Submitted	December 9, 2004	

8	Collins et al. (1999) "Support plasmids and support proteins required for recovery of recombinant respiratory syncytial virus" <u>Virology</u> 259:251-255	
9	Hardy & Wertz (2000) "The Cys(3)-His(1) motif of the respiratory syncytial virus M2-1 protein is essential for protein function" <u>J. Virol.</u> 74(13):5880-5.	
10	Jin et al. (1998) "Recombinant human respiratory syncytial virus (RSV) from cDNA and construction of subgroup A and B chimeric RSV" <u>Virology</u> 251:206-214	
11	Jin et al. (2000) "Respiratory syncytial virus that lacks open reading frame 2 of the M2 gene (M2-2) has altered growth characteristics and is attenuated in rodents" <u>J. Virol.</u> 74:74-82;	
12	Jin et al. (2000) "Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2 genes are attenuated in vitro and in vivo" <u>Virology</u> 273:210-218;	
13	Jin et al. (2003) "Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates" <u>Vaccine</u> 21:3647-3652	
14	Karron et al. (1997) "Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant" <u>Proc Natl Acad Sci USA</u> 94:13961-13966	
15	Tang et al. (2001) "Requirement of cysteines and length of the human respiratory syncytial virus M2-1 protein for protein function and virus viability" <u>J. Virol.</u> 75:11328-11335	
16	Techaarpornkul et al. (2001) "Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene" <u>J Virol</u> 75:6825-34	
17	Teng et al. (2000) "Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees" <u>J Virol</u> 74:9317-9321;	
18	Teng et al. (2001) "Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo" <u>Virology</u> 289:283-96).	
19	Whitehead et al. (1999) "Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates" <u>J Virol</u> 73:9773-9780	
20	GenBank accession number: M73544	
21	GenBank accession number: S75820	
22	GenBank accession number: D00334	
23	GenBank accession number: D00392	
24	GenBank accession number: D00393	

Examiner Signature	Stacy B Chen	Date Considered	1/3/06
--------------------	--------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A-B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>	<b>Complete if Known</b>	
	Application Number	10/811,508
	Filing Date	March 26, 2004
	First Named Inventor	Xing Cheng
	Group Art Unit	1659 1648
	Examiner Name	Unassigned Chen
	Attorney Docket Number	26-003820US
Date Submitted	December 9, 2004	

25	GenBank accession number: D00394	
26	GenBank accession number: D00395	
27	GenBank accession number: D00396	
28	GenBank accession number: D00397	
29	GenBank accession number: D00736	
30	GenBank accession number: D01042	
31	GenBank accession number: M17213	
32	GenBank accession number: AF013254	

Examiner Signature	Stacy B. Chen	Date Considered	1/3/06
-----------------------	---------------	--------------------	--------


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)



## Complete if Known

Application Number	10/811,508
Filing Date	March 26, 2004
First Named Inventor	Xing Cheng
Group Art Unit	1653/1648
Examiner Name	Unassigned Chen, Stacy
Attorney Docket Number	26-003820US
Date Submitted	January 6, 2005

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
SBC	1	Sullender (2002) "Respiratory Syncytial Virus Genetic and Antigenic Diversity" <u>Clinical Microbiology Reviews</u> , 13(1): 1-15.	

Examiner Signature	Stacy B. Chen	Date Considered	1/3/06
-----------------------	---------------	--------------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.